Triamcinolone Acetonide Injectable Suspension (Xipere) — CPB 1000 | AETNA Coverage Update

Aetna modified CPB 1000 covering Xipere (triamcinolone acetonide injectable suspension), effective September 26, 2025. Here's what billing teams need to do.

Aetna updated CPB 1000 governing suprachoroidal corticosteroid injection. This Aetna Xipere coverage policy applies to commercial medical plans and covers CPT 67516 and HCPCS J3299 when specific selection criteria are met. If you bill for retinal or uveitis services, this update affects your charge capture and diagnosis code pairing starting September 26, 2025.

Quick-Reference Table

Aetna Xipere Coverage Criteria and Medical Necessity Requirements 2025

The Aetna Xipere coverage policy under CPB 1000 covers CPT 67516 (suprachoroidal space injection of pharmacologic agent) when specific selection criteria are met. The policy also covers HCPCS J3299, billed per 1 mg of triamcinolone acetonide (Xipere). Both codes require supporting diagnosis codes from a defined ICD-10-CM list — covered diagnoses include secondary infectious iridocyclitis and retinal edema.

Aetna's coverage policy links reimbursement directly to those indications, so diagnosis code selection is not a formality — it's the gate to payment.

For Medicare criteria, Aetna explicitly directs providers to the separate Medicare Part B step criteria. CPB 1000 applies to commercial plans only. Don't apply commercial criteria to Medicare patients and vice versa — that's a fast path to a claim denial.

Confirm your plan-level requirements before the procedure date. Billing CPT 67516 without confirming coverage and authorization status will result in denials even when the diagnosis is correct.

Coverage Indications at a Glance

Aetna Xipere Billing Guidelines and Action Items 2025

This policy is narrow by design. Two codes, ten diagnosis codes, one drug. That simplicity is helpful — but it also means there's no room for loose diagnosis pairing. Here's what your billing team needs to do before and after September 26, 2025.

CPT, HCPCS, and ICD-10 Codes for Xipere Under CPB 1000

Covered CPT and HCPCS Codes (When Selection Criteria Are Met)

Key ICD-10-CM Diagnosis Codes

A note on the ICD-10 list: All nine H20.3x codes describe secondary infectious iridocyclitis. The policy lists all nine, which is standard — but your job is to pick the right one from the documentation, not to use the same code on every claim. H35.81 covers retinal edema broadly, so confirm the clinical record supports that diagnosis explicitly before billing it.

What the ICD-10 Code Range Tells You About This Policy

Nine of the ten diagnosis codes in CPB 1000 are variations of secondary infectious iridocyclitis (H20.31–H20.39). The tenth code — H35.81 for retinal edema — extends coverage slightly broader, but not by much.

This is a tight policy. Aetna isn't opening the door to off-label use. If a physician is treating a uveitis patient whose diagnosis doesn't map to H20.3x or H35.81, that claim has real denial risk. The medical necessity case for Xipere outside this code list doesn't exist in CPB 1000.

The real issue here is documentation. Ophthalmologists treating uveitis-associated macular edema often document the underlying condition more clearly than the resulting edema. Make sure your coding team captures both when both are present. The diagnosis that drives Xipere reimbursement needs to be in the chart before the claim goes out.